SOCM
CRSP icon

SR One Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

SR One Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$97M Hold
2,038,763
– – 10.59% 4
2025
Q4 		$107M Hold
2,038,763
– – 15.14% 3
2025
Q3 		$132M Buy
2,038,763
+989,812
+94% +$56.8M 19.11% 2
2025
Q2 		$51M Hold
1,048,951
– – 11.06% 3
2025
Q1 		$35.7M Hold
1,048,951
– – 9.17% 5
2024
Q4 		$41.3M Hold
1,048,951
– – 10.07% 3
2024
Q3 		$49.3M Hold
1,048,951
– – 9.88% 4
2024
Q2 		$56.7M Hold
1,048,951
– – 17.74% 2
2024
Q1 		$71.5M Buy
+1,048,951
New +$75.1M 19.64% 2

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

SR One Capital Management's CRSP Position: Q1 2026 in Review

SR One Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 2,038,763 shares worth $97M. The position accounts for 10.59% of the portfolio, ranked #4.

SR One Capital Management first reported a position in CRSP in Q1 2024 and has held it in 9 quarters since. The position peaked at $132M in Q3 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • SR One Capital Management held 2,038,763 shares of CRISPR Therapeutics worth $97M as of Q1 2026.
  • SR One Capital Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
  • CRISPR Therapeutics made up 10.59% of SR One Capital Management's portfolio in Q1 2026, its #4 holding.
  • SR One Capital Management first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • SR One Capital Management's CRISPR Therapeutics position peaked at $132M in Q3 2025.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on SR One Capital Management's 13F filing for Q1 2026, filed 14 May 2026.